These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30401713)

  • 21. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
    Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
    Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
    Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
    BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.
    Li T; Wang YN; Khokhlova TD; D'Andrea S; Starr F; Chen H; McCune JS; Risler LJ; Mashadi-Hossein A; Hingorani SR; Chang A; Hwang JH
    Cancer Res; 2015 Sep; 75(18):3738-46. PubMed ID: 26216548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
    Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
    PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
    Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
    Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
    Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
    [No Abstract]   [Full Text] [Related]  

  • 29. Stroma and pancreatic ductal adenocarcinoma: an interaction loop.
    Luo G; Long J; Zhang B; Liu C; Xu J; Ni Q; Yu X
    Biochim Biophys Acta; 2012 Aug; 1826(1):170-8. PubMed ID: 22521638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stromal biology and therapy in pancreatic cancer: a changing paradigm.
    Neesse A; Algül H; Tuveson DA; Gress TM
    Gut; 2015 Sep; 64(9):1476-84. PubMed ID: 25994217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophages and pancreatic ductal adenocarcinoma.
    Habtezion A; Edderkaoui M; Pandol SJ
    Cancer Lett; 2016 Oct; 381(1):211-6. PubMed ID: 26708507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
    Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
    Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
    Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
    Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.
    Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J
    Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH
    Cancer Cell; 2012 Jun; 21(6):822-35. PubMed ID: 22698406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
    Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
    Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
    Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
    Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
    Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
    Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
    Chen X; Zhou W; Liang C; Shi S; Yu X; Chen Q; Sun T; Lu Y; Zhang Y; Guo Q; Li C; Zhang Y; Jiang C
    Nano Lett; 2019 Jun; 19(6):3527-3534. PubMed ID: 31058513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.